Conducting a clinical trial in a rare gastrointestinal (GI) disease presents significant operational and logistical challenges. These studies require meticulous coordination, sustained resource allocation, and timely execution to meet protocol and enrollment goals. For Gastro One, success in such a complex setting was made possible through targeted operational support from Iterative Health.
Within approximately five months, the site achieved record enrollment metrics, including two patient randomizations in a Phase 1b-A trial. Given the rarity of the condition and the difficulty of identifying eligible candidates, this outcome reflects the effectiveness of the collaboration and the strategic value of integrated site support services.
Download the full case study (PDF)
Key Outcomes
- 2x faster site activation
- Higher patient retention
- Increased randomizations
- Over 50% of enrollments sourced through Iterative Health
- 4-month acceleration toward a multi-million dollar opportunity
Partnering with Iterative Health: High-Impact Operational Support
Gastro One didn’t just get a partner. They got what they call an “A+ startup.” Iterative Health provided hands-on, high-touch operational support in several critical areas to reduce site burden and accelerate progress.
Key Areas of Support
- Proactive chart reviews for scheduled patients
- Regulatory support to streamline setup
- Clear and consistent sponsor communication
- Strategic candidate identification to ensure speed and accuracy
- Reduced bandwidth strain on site teams
From the Front Lines: A Site’s Perspective
“We leaned on Iterative Health to prevent us from losing good patient candidates. Their communication and extra support on chart reviews for scheduled patients were key for my team, who are already stretched thin.” – Ziad Younes, MD | Gastro One
The Bottom Line: Speed, Efficiency, and Value
This collaboration enabled Gastro One to move faster, screen smarter, and deliver more without overburdening their internal team. With Iterative Health, they not only reduced trial costs and delays but also unlocked real opportunity.
About Iterative Health
Iterative Health is a healthcare technology and services company powering the acceleration of clinical research to transform patient outcomes. By combining deep expertise in clinical trials with cutting-edge AI, we empower research teams and study sponsors to expand and expedite access to novel therapeutics for patients in need. Today, Iterative Health is based in Cambridge, Massachusetts, and New York City with 250+ employees world-wide.
To learn more or explore a partnership, please visit our Contact page.